Treatment with ustekinumab leads to significant reductions in severe flares in systemic lupus erythematosus (SLE) patients with active disease, 1-year data from a Phase 2 trial shows. Biomarker analyses of the same data also provided clues about how ustekinumab works in SLE. The data were presented at the…
One year of treatment with ustekinumab led to sustained reductions in disease activity in systemic lupus erythematosus (SLE) patients, according to a Phase 2 trial. These benefits were also observed in patients who switched from placebo to Janssen‘s therapy at week 24. Trial findings were presented in the study, “…
Janssen announced that its investigational antibody Stelara (ustekinumab) showed positive results in a Phase 2 trial as a therapy for patients with systemic lupus erythematosus (SLE). Based on these results, the company said it would further test Stelara in a Phase 3 development program planned for 2018. The study, “Efficacy and…